SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of January 2024

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒       Form 40-F  ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

 

 

 

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1  Update - Proposed issue of securities - ATH

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Alterity Therapeutics Limited
   
  By:  /s/ Geoffrey P. Kempler
    Geoffrey P. Kempler
    Chairman

 

Date: January 5, 2024

 

 

2

 

Exhibit 99.1

 

Proposed issue of securities

 

Update Summary  
   

 

Entity name

ALTERITY THERAPEUTICS LIMITED

 

Announcement Type

Update to previous announcement

 

Date of this announcement

5/1/2024

 

Reason for update to a previous announcement

Proposed issue of securities approved by shareholders at EGM held 29 December 2023.

 

Refer to next page for full details of the announcement

 

Proposed issue of securities1 / 8 

 

 

Proposed issue of securities

 

Part 1 - Entity and announcement details  
   

 

1.1Name of +Entity

ALTERITY THERAPEUTICS LIMITED

 

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

 

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

 

1.2Registered Number Type Registration Number
ABN 37080699065

 

1.3ASX issuer code

ATH

 

1.4The announcement is

 Update/amendment to previous announcement

 

1.4a Reason for update to a previous announcement

Proposed issue of securities approved by shareholders at EGM held 29 December 2023.

 

1.4 b Date of previous announcement to this update

22/11/2023

 

1.5Date of this announcement

5/1/2024

 

1.6The Proposed issue is:

 A placement or other type of issue

 

Proposed issue of securities2 / 8 

 

 

Proposed issue of securities

 

Part 7 - Details of proposed placement or other issue  
   

 

Part 7A - Conditions  
   

 

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

 Yes

 

7A.1a Conditions

 

Approval/Condition Date for determination Is the date estimated or actual? ** Approval
received/condition met?
+Security holder approval 29/12/2023  Actual yes

 

Comments

 

 

Part 7B - Issue details  
   

 

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?   Will the proposed issue of this +security include an offer of attaching +securities?
Existing class   yes

 

Details of +securities proposed to be issued

 

ASX +security code and description 

ATH : ORDINARY FULLY PAID

 

Number of +securities proposed to be issued

1,008,965,809

 

Offer price details

 

Are the +securities proposed to be issued being issued for a cash consideration?

Yes

 

Proposed issue of securities3 / 8 

 

 

Proposed issue of securities

 

In what currency is the cash consideration being paid?   What is the issue price per +security?
AUD - Australian Dollar   AUD 0.00350

 

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

 

Attaching +Security

 

Is the proposed attaching security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional +securities in a class that is already quoted or recorded by ASX)?

New class

 

Attaching +Security - New class (+securities in a class that is not yet quoted or recorded by ASX)

 

Details of attaching +securities proposed to be issued

 

ISIN Code (if Issuer is a foreign company and +securities are non CDIs)

 

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?   Will the entity be seeking quotation of the 'new' class of +securities on ASX?
No   No

 

ASX +security code   +Security description
New class-code to be confirmed   Short-dated option

 

+Security type

Options

 

Number of +securities proposed to be issued

1,371,428,571

 

Offer price details

 

Are the +securities proposed to be issued being issued for a cash consideration?

No

 

Please describe the consideration being provided for the +securities

One (1) free attaching short-dated option issued for each Placement share issued per Placement announcement 22 Nov 2023

 

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

 

Proposed issue of securities4 / 8 

 

 

Proposed issue of securities

 

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

 

Options details

 

+Security currency

AUD - Australian Dollar

 

Exercise price   Expiry date
AUD 0.0070   31/8/2024

 

Details of the type of +security that will be issued if the option is exercised

ATH : ORDINARY FULLY PAID

 

Number of securities that will be issued if the option is exercised

One ATH fully paid ordinary share

 

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

https://alteritytherapeutics.com/investor-overview/asx-announcements/

 

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?   Will the proposed issue of this +security include an offer of attaching +securities?
New class   No

 

Details of +securities proposed to be issued

 

ISIN Code (if Issuer is a foreign company and +securities are non CDIs)

 

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?   Will the entity be seeking quotation of the 'new' class of +securities on ASX?
No   Yes

 

ASX +security code   +Security description
New class-code to be confirmed   Long-dated options

 

+Security type

Options

 

Proposed issue of securities5 / 8 

 

 

Proposed issue of securities

 

Number of +securities proposed to be issued

457,142,857

 

Offer price details

 

Are the +securities proposed to be issued being issued for a cash consideration?

No

 

Please describe the consideration being provided for the +securities

One (1) free attaching long-dated option issued for each three (3) Placement shares issued per Placement announcement 22Nov 2023

 

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

 

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

 

Options details

 

+Security currency Exercise price Expiry date
AUD - Australian Dollar AUD 0.0100 31/8/2026

 

Details of the type of +security that will be issued if the option is exercised

ATH : ORDINARY FULLY PAID

 

Number of securities that will be issued if the option is exercised

One ATH fully paid ordinary share

 

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

https://alteritytherapeutics.com/investor-overview/asx-announcements/

 

Part 7C - Timetable  
   

 

7C.1 Proposed +issue date

8/1/2024

 

Proposed issue of securities6 / 8 

 

 

Proposed issue of securities

 

Part 7D - Listing Rule requirements  
   

 

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

Yes

 

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

29/12/2023

 

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

Yes

 

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

 

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No

 

Part 7E - Fees and expenses  
   

 

7E.1 Will there be a lead manager or broker to the proposed issue?

Yes

 

7E.1a Who is the lead manager/broker?

MST Financial Services Pty Ltd

 

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

6% of amount raised under Placement

 

7E.2 Is the proposed issue to be underwritten?

No

 

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

                 

 

Part 7F - Further Information  
   

 

7F.01 The purpose(s) for which the entity is issuing the securities

The use of proceeds from this financing will provide ongoing funding of Alterity's Phase 2 clinical trials in MSA, planning for a Phase 3 clinical trial, continuing discovery and research efforts and general working capital.

 

Proposed issue of securities7 / 8 

 

 

Proposed issue of securities

 

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

 

7F.2 Any other information the entity wishes to provide about the proposed issue

                 

 

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)

 

Proposed issue of securities8 / 8 


Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alterity Therapeutics Charts.
Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alterity Therapeutics Charts.